在COPD恶化患者中,通过不同的雾化剂给药的支气管扩展剂的反应
Breda Cushen1, Abir Alsaid2, Garrett Greene3
1Department of Respiratory Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; and Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland. bredacushen@rcsi.ie.
Respiratory care
|June 6, 2023
概括
与小体积喷射雾化器 (SVN) 相比,振动网状雾化器 (VMN) 可能为COPD恶化提供更好的缓解症状. 这项研究发现,VMNs导致呼吸困难和肺功能得到更大的改善,这表明在COPD管理中具有潜在的益处.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 医疗器械 医疗器械
背景情况:
- 慢性肺炎恶化需要支气管扩展剂治疗以缓解支气管收缩和呼吸困难.
- 振动网状雾化器 (VMNs) 在体外呼吸道药物输送优于标准小容量喷射雾化器 (SVNs).
- 在COPD恶化中,VMN与SVN在支气管扩展剂的临床有效性需要研究.
研究的目的:
- 为了比较通过VMN输送的支气管扩展剂的生理和症状反应与在COPD恶化后住院的患者中的SVN.
- 为了评估两种雾化器类型之间的螺旋计,肺体积,呼吸道阻抗和喘息得分的差异.
主要方法:
- 一项临床有效性比较研究,涉及32名住院COPD恶化患者.
- 在一项开放式随机试验中,参与者通过VMN (n=16) 或SVN (n=16) 接受单剂量萨尔布塔摩尔/伊普拉.
- 螺旋测量,体积测量,冲动振荡测量和博格呼吸困难得分在支气管扩张前和后被测量.
主要成果:
- 两组VMN和SVN都显示了肺体积和气道阻抗的显著变化.
- 与SVN组相比,VMN组的强迫生命能力 (FVC) 增加更大 (P=.053) 和Borg气喘得分显著降低 (P=.034).
- 在VMN和SVN组之间没有观察到灵感能力 (IC) 变化的实质差异.
结论:
- 与SVN相比,通过VMN给予等效剂量的支气管扩展剂导致症状改善更大,FVC绝对变化更大.
- 在COPD恶化期间,VMN可能为支气管扩展剂提供更有效的输送方法,从而更好地缓解症状.
- 需要进一步的研究来证实这些发现,并探索VMNs在COPD管理中的长期益处.
相关概念视频
Inhaled Medications
323
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
323
COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
Antiasthma Drugs: β2-Adrenoceptor Agonists
318
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
318
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Drugs Used in Lower Respiratory Disorders: Overview
506
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
506
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K


